

Michael O Koch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9435464/publications.pdf>

Version: 2024-02-01

60
papers

1,006
citations

471509

17
h-index

477307

29
g-index

62
all docs

62
docs citations

62
times ranked

1523
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. <i>Human Genetics and Genomics Advances</i> , 2022, 3, 100070.	1.7	10
2	Role of Neoadjuvant Chemotherapy in Squamous Variant Histology in Urothelial Bladder Cancer: Does Presence and Percentage Matter?. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 47-52.	1.9	6
3	AUTHOR REPLY. <i>Urology</i> , 2021, 152, 189.	1.0	0
4	Longitudinal Health Related Quality of Life After Open Radical Cystectomy: Comparison of Ileal Conduit, Indiana Pouch, and Orthotopic Neobladder. <i>Urology</i> , 2021, 152, 184-189.	1.0	8
5	Focal High-Intensity Focused Ultrasound Ablation of the Prostate. <i>Journal of Endourology</i> , 2021, 35, S-24-S-32.	2.1	1
6	A novel, safe, fast and efficient treatment for Her2 α positive and negative bladder cancer utilizing an EGF α anthrax toxin chimera. <i>International Journal of Cancer</i> , 2020, 146, 449-460.	5.1	20
7	Robot-Assisted Radical Prostatectomy in Patients with a History of Holmium Laser Enucleation of the Prostate: The Indiana University Experience. <i>Journal of Endourology</i> , 2020, 34, 163-168.	2.1	14
8	Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 449-458.	1.6	14
9	Robotic and open partial nephrectomy for intermediate and high complexity tumors: a matched-pairs comparison of surgical outcomes at a single institution. <i>Scandinavian Journal of Urology</i> , 2020, 54, 313-317.	1.0	7
10	Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5019-5019.	1.6	32
11	Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)- eligible cohort of HCRN GU14-188.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5047-5047.	1.6	32
12	Clinicopathological characteristics of ypT0N0 urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. <i>Journal of Clinical Pathology</i> , 2019, 72, 550-553.	2.0	4
13	Dataset for reporting of carcinoma of the urethra (in urethrectomy specimens): recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Histopathology</i> , 2019, 75, 453-467.	2.9	3
14	Data Set for the Reporting of Carcinoma of the Renal Pelvis and Ureter α Nephroureterectomy and Ureterectomy Specimens. <i>American Journal of Surgical Pathology</i> , 2019, 43, e1-e12.	3.7	5
15	Cylindrical illumination with angular coupling for whole-prostate photoacoustic tomography. <i>Biomedical Optics Express</i> , 2019, 10, 1405.	2.9	8
16	Inherited forms of bladder cancer: a review of Lynch syndrome and other inherited conditions. <i>Future Oncology</i> , 2018, 14, 277-290.	2.4	19
17	Metabolic and Nutritional Consequences of Urinary Diversion Using Intestinal Segments to Reconstruct the Urinary Tract. <i>Urologic Clinics of North America</i> , 2018, 45, 19-24.	1.8	19
18	Editorial Comment. <i>Journal of Urology</i> , 2018, 200, 792-793.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Photoacoustic tomography of intact human prostates and vascular texture analysis identify prostate cancer biopsy targets. <i>Photoacoustics</i> , 2018, 11, 46-55.	7.8	22
20	Plasmacytoid urothelial carcinoma: A clinicopathological study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 482-482.	1.6	5
21	Survival outcomes in plasmacytoid urothelial carcinoma: Results with contemporary systemic therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16525-e16525.	1.6	0
22	Prognostic Effect of Carcinoma In Situ in Muscle-invasive Urothelial Carcinoma Patients Receiving Neoadjuvant Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 479-486.	1.9	5
23	Preoperative Nomograms for Predicting Renal Function at 1 Year After Partial Nephrectomy. <i>Journal of Endourology</i> , 2017, 31, 711-718.	2.1	15
24	Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy. <i>BJU International</i> , 2017, 119, 816-816.	2.5	1
25	Estimation of radiation dosimetry for ⁶⁸ Ga-HBED-CC (PSMA-11) in patients with suspected recurrence of prostate cancer. <i>Nuclear Medicine and Biology</i> , 2017, 46, 32-35.	0.6	18
26	Long-term Health-related Quality of Life Outcomes Following Radical Cystectomy. <i>Urology</i> , 2017, 106, 82-86.	1.0	21
27	Liquid Biopsies in the Management of Bladder Cancer: Next-Generation Biomarkers for Diagnosis, Surveillance, and Treatment-Response Prediction. <i>Critical Reviews in Oncogenesis</i> , 2017, 22, 389-401.	0.4	7
28	Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives. <i>Current Drug Metabolism</i> , 2017, 18, 700-711.	1.2	25
29	Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence. <i>Cancer Biomarkers</i> , 2016, 17, 83-88.	1.7	15
30	Impact of Obesity on Wound Complications Following Radical Prostatectomy Is Mitigated by Robotic Technique. <i>Journal of Endourology</i> , 2016, 30, 890-895.	2.1	12
31	Robotic versus Open Prostatectomy: End of the Controversy. <i>Journal of Urology</i> , 2016, 196, 9-10.	0.4	17
32	High Intensity Focused Ultrasound is a Good Treatment Option for Localized Prostate Cancer. <i>Journal of Urology</i> , 2016, 196, 1610-1612.	0.4	0
33	Editorial Comment. <i>Journal of Urology</i> , 2016, 195, 1414-1414.	0.4	0
34	Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histology. <i>Future Oncology</i> , 2016, 12, 1795-1804.	2.4	11
35	Identification of novel immunomodulatory tumor biology through comprehensive characterization of a metastases-specific epigenome in patients with metachronous primary and metastatic urothelial carcinoma (UC) tumor pairs.. <i>Journal of Clinical Oncology</i> , 2016, 34, 452-452.	1.6	20
36	Phase 2 trial of dovitinib in Bacillus Calmette-Guerin (BCG) refractory urothelial carcinoma (UC) with tumor FGFR3 mutations or over-expression: Hoosier Cancer Research Network GU12-157.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4526-4526.	1.6	3

#	ARTICLE	IF	CITATIONS
37	Human papillomavirus (HPV)-induced neoplasia in the urinary bladder: a missing link?. <i>Histology and Histopathology</i> , 2016, 31, 595-600.	0.7	8
38	Functional and Clinicopathologic Outcomes Using a Modified Vescica Ileale Padovana Technique. <i>Bladder Cancer</i> , 2015, 1, 73-79.	0.4	4
39	Robot-Assisted Radical Prostatectomy in Patients with a History of Holmium Laser Enucleation of the Prostate: Feasibility and Evaluation of Initial Outcomes. <i>Journal of Endourology</i> , 2015, 29, 764-769.	2.1	23
40	Oncologic and quality-of-life outcomes with wide resection in robot-assisted laparoscopic radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 70.e9-70.e14.	1.6	4
41	Does Squamous Differentiation Portend Worse Outcomes in Urothelial Bladder Cancer?. <i>Urology Practice</i> , 2015, 2, 335-342.	0.5	2
42	The changing reality of urothelial bladder cancer: should non-squamous variant histology be managed as a distinct clinical entity?. <i>BJU International</i> , 2015, 116, 236-240.	2.5	10
43	Lymph node metastases in patients with urothelial carcinoma variants: Influence of the specific variant on nodal histology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 20.e23-20.e29.	1.6	20
44	Contemporary bladder cancer: Variant histology may be a significant driver of disease. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 18.e15-18.e20.	1.6	75
45	Oncologic outcomes and prognostic impact of urothelial recurrences in patients undergoing segmental and total ureterectomy for upper tract urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2015, 9, 187.	0.6	17
46	Molecular characteristics of urothelial neoplasms in children and young adults: a subset of tumors from young patients harbors chromosomal abnormalities but not FGFR3 or TP53 gene mutations. <i>Modern Pathology</i> , 2014, 27, 1540-1548.	5.5	19
47	Plasmacytoid Bladder Cancer: Variant Histology With Aggressive Behavior and a New Mode of Invasion Along Fascial Planes. <i>Urology</i> , 2014, 83, 1112-1116.	1.0	62
48	EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder. <i>Modern Pathology</i> , 2014, 27, 107-112.	5.5	12
49	Critical analysis of the 2010 TNM classification in patients with lymph node-positive bladder cancer: Influence of lymph node disease burden. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1003-1009.	1.6	9
50	Plasmacytoid variant urothelial bladder cancer: Is it time to update the treatment paradigm? Contributed equally to manuscript.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 833-838.	1.6	54
51	Incidence and Risk Factors of Parastomal Hernia in Patients Undergoing Radical Cystectomy and Ileal Conduit Diversion. <i>Journal of Urology</i> , 2014, 191, 1313-1318.	0.4	59
52	Short-term morbidity and mortality of Indiana pouch, ileal conduit, and neobladder urinary diversion following radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1151-1157.	1.6	35
53	National trends in the utilization of robotic-assisted radical cystectomy: An analysis using the Nationwide Inpatient Sample. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 785-790.	1.6	30
54	The Expression Patterns of p53 and p16 and an Analysis of a Possible Role of HPV in Primary Adenocarcinoma of the Urinary Bladder. <i>PLoS ONE</i> , 2014, 9, e95724.	2.5	18

#	ARTICLE	IF	CITATIONS
55	Consolidation cystectomy after induction chemotherapy in node-positive urothelial bladder cancer.. Journal of Clinical Oncology, 2014, 32, e15520-e15520.	1.6	0
56	Should the Patient With Positive Margins After Radical Prostatectomy Receive Adjuvant Radiation?. Journal of Urology, 2010, 184, 1838-1839.	0.4	1
57	Thermal-based treatment options for localized prostate cancer. Current Treatment Options in Oncology, 2005, 6, 379-387.	3.0	5
58	AORTIC REPLACEMENT DURING POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION. Journal of Urology, 2001, 165, 1517-1520.	0.4	47
59	ACCURACY OF PREDICTING LONG-TERM PROSTATE SPECIFIC ANTIGEN OUTCOME BASED ON EARLY PROSTATE SPECIFIC ANTIGEN RECURRENCE RESULTS AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2001, 166, 2198-2201.	0.4	15
60	Cytokeratin 7 and Cytokeratin 20 in Primary Urinary Bladder Carcinoma and Matched Lymph Node Metastasis. Archives of Pathology and Laboratory Medicine, 2001, 125, 921-923.	2.5	73